Two important maternal cardiometabolic disorders (CMDs), hypertensive disorders in
pregnancy (HDP)(including pre-eclampsia) and gestational diabetes mellitus (GDM), result …

Preeclampsia is defined as new-onset hypertension after the 20th wk of gestation along with
evidence of maternal organ failure. Rates of preeclampsia have steadily increased over the …

Fetal growth restriction (FGR) is defined as the failure of the fetus to meet its growth potential
due to a pathological factor, most commonly placental dysfunction. Worldwide, FGR is a …

Preeclampsia is an obstetric disorder that affects 3–8% of pregnant women and remains a
leading cause of short-and long-term neonatal and maternal morbidity and mortality …

Fetal growth restriction and related placental pathologies such as preeclampsia, stillbirth,
and placental abruption are believed to arise in early pregnancy when inadequate …

During pregnancy, development of the placenta is interrelated with the oxygen
concentration. Embryo development takes place in a low oxygen environment until the …

Preeclampsia is a common pregnancy complication, affecting 2% to 8% of pregnancies
worldwide, and is an important cause of both maternal and fetal morbidity and mortality …

Preeclampsia (PE) is a pregnancy-specific disorder affecting 4–10% of all expectant women.
It greatly increases the risk of maternal and foetal death. Although the main symptoms …

Preeclampsia is a major pregnancy complication where excess placental release of soluble
fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin causes maternal endothelial and …

There has been increasing research momentum to identify new therapeutic agents for the
prevention or treatment of preeclampsia, drugs that can affect the underlying disease …